Supplementary Table 1 Endpoints of included studies

Ref.	HN	GI	HE	Severe Infection#	PICD	Ascites	SBP	HRS	Renal impairment	Hospital stay (days)	Mortality	PE	AE	In hospital mortality
Ginès *et al*, 1988[49]	a	a	a	a		a			a	a	a	a		a
Sola-Vera *et al*., 2003[52]	a	a		a	a	a	a		a	a				a
Compean *et al*., 2002[48]	a					a		a	a	a	a			a
Planas *et al*., 1990[50]	a	a	a	a		a	a		a	a	a	a		a
Bajaj *et al*., 2018[53]	a						a							a
Singh *et al*.,	a				a	a			a					

2006[54]										
Moreau *et al*., 2002[55]	a						a			
Salerno *et al*., 1991[56]	a	a	a	a	a		a	a		a
García-Compeán *et al*., 1993[57]	a		a				a		a	a
Fassio *et al*., 1992[58]	a		a		a	a	a			a
Altman *et al*., 1998[59]	a	a	a	a			a			
Singh *et al*.,							a			

2006[60]													
Appenrodt *et al*., 2008[37]	a				a			a	a				a
Abdel-Khalek and Arif, 2020[13]	a	a	a	a	a	a			a	a	a		a
Salerno *et al*., 1987[61]	a	a	a						a			a	a
Moreau *et al*., 2006[62]	a	a	a	a			a		a				
Jalan *et al*., 2007[63]			a	a									a

Sort *et al.*, 1999[64]			a						a			a
Bari *et al.*, 2012[65]				a			a				a	
Solà *et al.*, 2018[25]											a	
Caraceni *et al.*, 2018[24]											a	
Hu *et al.*, 2023[38]										a		a
Khanna *et al*, 2024[66]	a	a			a	a	a	a		a		
Pascoli *et al*, 2018[67]	a	a			a	a	a			a		
Guevara *et al*, 2012[68]							a	a		a		

Thévenot etal, 2014[69]	a										a						a			a
Devisetty *et al*, 2023[70]															a		a			a
Simón-Talero *et al.*, 2013[71]	a	a													a		a			
Romanelli *et al.*, 2006[72]	a	a					a		a											
Abootalebi *et al.*, 2017[73]																				
Boyer *et al.*, 2016[74]												a					a		a	

AE: Adverse event; GI: Gastrointestinal bleeding; HE: Hepatic encephalopathy; HN: Hyponatremia; HRS: Hepatorenal syndrome; PICD: Post paracentesis circulatory dysfunction; PE: Peripheral edema; SBP: Spontaneous bacterial peritonitis#complication arising during hospitalization.



Supplementary Figure 1 Forest plot comparing albumin with other treatment groups for post paracentesis circulatory dysfunction. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.



Supplementary Figure 2 Forest plot comparing albumin with other treatment groups for severe infection. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


Author(s) and Year
Albumin
Events Total
Control
Events Total
Weights Odds Ratio [95% CI]
Salerno et al_1987 0 20 2 21 2.40% 0.19 [0.01, 4.22]
Ginès et al_1988 2 52 1 53 3.89% 2.08 [0.18, 23.67]
Sola-Vera et al_2003 1 37 0 35 2.20% 2.92 [0.11, 74.04]
Khanna et al_2014 13 88 15 86 35.04% 0.82 [0.36, 1.85]
Pascoli et al_2018 1 45 1 25 2.90% 0.55 [0.03, 9.12]
Thévenot etal_2014 3 95 4 96 9.90% 0.75 [0.16, 3.44]
Simón-Talero et al._2013 1 26 3 30 4.25% 0.36 [0.04, 3.69]
Romanelli et al._2006 5 54 10 46 17.21% 0.37 [0.12, 1.17]
Salerno et al_1991 3 27 0 27 2.54% 7.86 [0.39, 159.85]
Moreau et al_2006 4 30 3 38 9.21% 1.79 [0.37, 8.72]
Altman et al_1998 0 33 1 27 2.19% 0.26 [0.01, 6.74]
Planas et al_1990 1 43 3 45 4.34% 0.33 [0.03, 3.34]
Abdel-Khalek and Arif_2010 1 68 2 67 3.92% 0.49 [0.04, 5.48]
FE Model for All Studies (Q = 8.54, df = 12, p = 0.74; I^2 = 0.0%, τ^2 = 0.00) 100% 0.73 [0.45, 1.18]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B


Author(s) and Year
Albumin
Events
Total
Control
Events
Total
Weights
Odds Ratio [95% CI]
Volume expander
Abdel-Khalek and Arif, 2010 1 68 2 67 3.92% 0.49 [0.04, 5.48]
Planas et al, 1990 1 43 3 45 4.34% 0.33 [0.03, 3.34]
Altman et al, 1998 0 33 1 27 2.19% 0.26 [0.01, 6.74]
Moreau et al, 2006 4 30 3 38 9.21% 1.79 [0.37, 8.72]
Salerno et al, 1991 3 27 0 27 2.54% 7.86 [0.39, 159.85]
FE Model for Subgroup (Q = 4.19, df = 4, p = 0.38; I² = 0.0%, τ² = 0.00) 1.00 [0.36, 2.78]
Inactives/Standard medical treatment
Romanelli et al., 2006 5 54 10 46 17.21% 0.37 [0.12, 1.17]
Simón-Talero et al., 2013 1 26 3 30 4.25% 0.36 [0.04, 3.69]
Thévenot etal, 2014 3 95 4 96 9.90% 0.75 [0.16, 3.44]
Pascoli et al, 2018 1 45 1 25 2.90% 0.55 [0.03, 9.12]
Khanna et al, 2014 13 88 15 86 35.04% 0.82 [0.36, 1.85]
Sola-Vera et al, 2003 1 37 0 35 2.20% 2.92 [0.11, 74.04]
Ginès et al, 1988 2 52 1 53 3.89% 2.08 [0.18, 23.67]
Salerno et al, 1987 0 20 2 21 2.40% 0.19 [0.01, 4.22]
FE Model for Subgroup (Q = 3.85, df = 7, p = 0.80; I² = 0.0%, τ² = 0.00) 0.66 [0.39, 1.14]
FE Model for All Studies (Q = 8.54, df = 12, p = 0.74; I² = 0.0%, τ² = 0.00) 100% 0.73 [0.45, 1.18]
Test for Subgroup Differences: Q_M = 0.49, df = 1, p = 0.48
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

Supplementary Figure 3 Forest plot for gastrointestinal bleeding comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for gastrointestinal (GI) bleeding comparing albumin and control; B: Forest plot for GI bleeding comparing albumin *vs* control across other treatment groups.95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


Author(s) and Year
Albumin
Events Total
Control
Events Total
Weights Odds Ratio [95% CI]
Ginès et al_1988 6 52 3 53 6.17% 2.17 [0.51, 9.20]
Jalan et al_2007 1 12 5 12 2.33% 0.13 [0.01, 1.33]
García-Compeán et al_1993 1 17 0 18 1.20% 3.36 [0.13, 88.39]
Salerno et al_1987 2 20 1 21 2.08% 2.22 [0.19, 26.63]
Salerno et al_1987 2 20 3 21 3.54% 0.67 [0.10, 4.48]
Khanna et al_2014 14 88 32 86 24.82% 0.32 [0.16, 0.66]
Pascoli et al_2018 12 45 16 25 11.64% 0.20 [0.07, 0.58]
Simón-Talero et al._2013 5 26 6 30 7.33% 0.95 [0.25, 3.58]
Romanelli et al._2006 11 54 11 46 14.31% 0.81 [0.32, 2.10]
Altman et al_1998 1 33 0 27 1.22% 2.54 [0.10, 64.86]
Planas et al_1990 3 43 3 45 4.67% 1.05 [0.20, 5.51]
Fassio et al_1992 1 21 2 20 2.08% 0.45 [0.04, 5.39]
Salerno et al_1991 2 27 2 27 3.10% 1.00 [0.13, 7.67]
Abdel-Khalek and Arif_2010 4 68 3 67 5.44% 1.33 [0.29, 6.20]
Moreau et al_2006 7 30 9 38 10.07% 0.98 [0.32, 3.03]
FE Model for All Studies (Q = 17.95, df = 14, p = 0.21; I^2 = 22.0%, τ^2 = 0.00) 100% 0.62 [0.44, 0.89]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 4 Forest plot for hepatic encephalopathy comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for hepatic encephalopathy (HE) comparing albumin and control; B: Forest plot for HE comparing albumin *vs* control across other treatment groups.95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


Author(s) and Year
Albumin Events Total
Control Events Total
Weights Odds Ratio [95% CI]
Ginès et al_1988 0 52 6 53 2.16% 0.07 [0.00, 1.27]
Sola-Vera et al_2003 2 37 3 35 5.31% 0.61 [0.10, 3.89]
García-Compeán et al_1993 1 17 2 18 2.92% 0.50 [0.04, 6.08]
Salerno et al_1987 1 20 1 21 2.26% 1.05 [0.06, 18.05]
Khanna et al_2014 6 88 22 86 19.78% 0.21 [0.08, 0.56]
Guevara et L_2012 3 46 4 51 7.56% 0.82 [0.17, 3.87]
Thévenot etal_2014 13 95 12 96 25.74% 1.11 [0.48, 2.57]
Singh et al_2006 # 1 20 1 20 2.25% 1.00 [0.06, 17.18]
Moreau et al_2002 0 10 0 10 1.13% 1.00 [0.02, 55.27]
Singh et al_2006 * 0 20 0 20 1.16% 1.00 [0.02, 52.85]
Appenrodt et al_2008 0 13 2 11 1.84% 0.14 [0.01, 3.28]
Compean et al_2002 7 48 2 48 6.89% 3.93 [0.77, 19.98]
Planas et al_1990 1 43 1 45 2.32% 1.05 [0.06, 17.29]
Salerno et al_1991 1 27 1 27 2.29% 1.00 [0.06, 16.85]
Fassio et al_1992 1 21 1 20 2.26% 0.95 [0.06, 16.29]
Altman et al_1998 0 33 0 27 1.17% 0.82 [0.02, 42.73]
Abdel-Khalek and Arif_2010 1 68 1 67 2.34% 0.99 [0.06, 16.08]
Moreau et al_2006 4 30 8 38 10.62% 0.58 [0.16, 2.14]
FE Model for All Studies (Q = 15.43, df = 17, p = 0.56; I^2 = 0.0%, τ^2 = 0.00) 100% 0.67 [0.44, 1.03]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 5 Forest plot for renal impairment comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for renal impairment comparing albumin and control; B: Forest plot for renal impairment comparing albumin *vs* control across other treatment groups. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect. # Singh V et al., J Gastroenterol Hepatol. 2006; *Singh V et al., J Intern Med. 2006.

A


Hospital stay days
Study
SMD [95% CI]
Ginès et al 1988
11.81%
-0.19 [-0.57, 0.20]
Sola vera et al 2003
8.13%
0.04 [-0.42, 0.51]
Devisetty et al 2023
17.47%
0.00 [-0.32, 0.32]
Simón-Talero et al. 2013
6.29%
0.00 [-0.53, 0.53]
Sort et al 1999
14.21%
0.13 [-0.22, 0.47]
Compean et al 2002
10.84%
-0.03 [-0.43, 0.37]
Planas et al 1990
9.92%
-0.11 [-0.53, 0.30]
Salerno et al 1991
6.07%
0.19 [-0.35, 0.72]
Abdel-Khalek and Arif 2010
15.25%
-0.00 [-0.34, 0.33]
Albumin is Better
Control is Better
Fixed-Effect Model
100%
-0.00 [-0.14, 0.13]
FE Model for All Studies: Q = 0.00, df = 8, p = 0.95
-1
-0.5
0
0.5
1
Standardized Mean Difference

B



Supplementary Figure 6 Forest plot for hospital stay days comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for hospital stay days comparing albumin and control; B: Forest plot for hospital stay days comparing albumin *vs* control across other treatment groups.95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect; SMD, standardized mean difference.

A


Author(s) and Year
Albumin
Events Total
Control
Events Total
Weights
Odds Ratio [95% CI]
Ginès et al_1988 10 52 11 53 8.49% 0.91 [0.35, 2.37]
Sola-Vera et al_2003 10 37 11 35 7.51% 0.81 [0.29, 2.24]
Khanna et al_2014 30 88 51 86 20.50% 0.35 [0.19, 0.66]
Pascoli et al_2018 17 45 18 25 6.91% 0.24 [0.08, 0.68]
Romanelli et al._2006 21 54 39 46 8.22% 0.11 [0.04, 0.30]
Singh et al_2006 2 20 1 20 1.26% 2.11 [0.18, 25.35]
Compean et al_2002 30 48 34 48 10.67% 0.69 [0.29, 1.61]
Planas et al_1990 18 43 15 45 10.35% 1.44 [0.61, 3.43]
Salerno et al_1991 13 27 10 27 6.59% 1.58 [0.53, 4.68]
Fassio et al_1992 6 21 5 20 4.05% 1.20 [0.30, 4.80]
Abdel-Khalek and Arif_2010 21 68 27 67 15.46% 0.66 [0.33, 1.35]
FE Model for All Studies (Q = 27.03, df = 10, p < .01; I^2 = 63.0%, τ^2 = 0.00) 100% 0.59 [0.44, 0.78]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 7 Forest plot for ascites reappearance comparing albumin and control and comparing albumin *vs* control across other treatment groups. A: Forest plot for ascites reappearance comparing albumin and control; B: Forest plot for ascites reappearance comparing albumin *vs* control across other treatment groups.95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


HRS
Author(s) and Year
Albumin
Events Total
Control
Events Total
Weights Odds Ratio[95% CI]
Khanna et al_2014 6 88 21 86 28.58% 0.23 [0.09, 0.59]
Guevara et L_2012 1 46 4 51 5.34% 0.26 [0.03, 2.43]
Pascoli et al_2018 10 45 14 25 23.76% 0.22 [0.08, 0.65]
Appenrodt et al_2008 0 13 1 11 2.44% 0.26 [0.01, 7.03]
Bari et al_2012 0 13 0 12 1.66% 0.93 [0.02, 50.29]
Boyer et al_2016 8 97 12 99 29.91% 0.65 [0.25, 1.67]
Compean et al_2002 1 48 3 48 5.02% 0.32 [0.03, 3.18]
Fassio et al_1992 1 21 1 20 3.29% 0.95 [0.06, 16.29]
FE Model for All Studies (Q = 3.93, df = 7, p = 0.79; I2 = 0.0%, τ2 = 0.00) 100% 0.34 [0.20, 0.57]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 8 Forest plot for hepatorenal syndrome comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for hepatorenal syndrome (HRS) comparing albumin and control; B: Forest plot for HRS comparing albumin *vs* control across other treatment groups.95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


SBP
Author(s) and Year
Albumin
Events
Total
Control
Events
Total
Weights Odds Ratio[95% CI]
Sola-Vera et al_2003 1 37 1 35 6.14% 0.94 [0.06, 15.71]
Khanna et al_2014 3 88 15 86 29.68% 0.17 [0.05, 0.60]
Pascoli et al_2018 4 45 13 25 29.08% 0.09 [0.02, 0.33]
Romanelli et al._2006 3 54 2 46 14.43% 1.29 [0.21, 8.10]
Planas et al_1990 0 43 2 45 5.17% 0.20 [0.01, 4.29]
Moreau et al_2006 2 30 4 38 15.50% 0.61 [0.10, 3.56]
FE Model for All Studies (Q = 7.71, df = 5, p = 0.17; I2 = 35.1%, τ2 = 0.00) 100% 0.26 [0.13, 0.52]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 9 Forest plot for spontaneous bacterial peritonitis comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for spontaneous bacterial peritonitis (SBP) comparing albumin and control; B: Forest plot for SBP comparing albumin *vs* control across other treatment groups. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


Author(s) and Year
Albumin
Events Total
Control
Events Total
Weights
Odds Ratio [95% CI]
Devisetty et al,_2023 14 58 23 116 10.61% 1.29 [0.60, 2.74]
Khanna et al,_2024 20 88 29 86 13.48% 0.58 [0.30, 1.13]
Pascoli et al,_2018 15 45 15 25 5.90% 0.33 [0.12, 0.92]
Guevara et L,_2012 8 46 10 51 5.71% 0.86 [0.31, 2.42]
Thévenot etal, 2014_2014 27 95 20 96 13.70% 1.51 [0.78, 2.93]
Simón-Talero et al._2013 6 26 14 30 4.49% 0.34 [0.11, 1.09]
Ginès et al_1988 18 52 14 53 8.65% 1.47 [0.64, 3.40]
Boyer et al.,_2016 40 97 43 99 18.82% 0.91 [0.52, 1.61]
Compean et al_2002 11 48 18 48 7.61% 0.50 [0.20, 1.21]
Planas et al_1990 11 43 15 45 7.09% 0.69 [0.27, 1.73]
Abdel-Khalek and Arif_2010 5 68 6 67 3.95% 0.81 [0.23, 2.78]
FE Model for All Studies (Q = 14.25, df = 10, p = 0.16; I^2 = 29.8%, τ^2 = 0.00) 100% 0.83 [0.65, 1.06]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 10 Forest plot for mortality during follow up comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for mortality during follow up comparing albumin and control; B: Forest plot for mortality during follow up comparing albumin *vs* control across other treatment groups. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


Peripheral edema
Author(s) and Year
Albumin
Events
Total
Control
Events
Total
Weights Odds Ratio[95% CI]
Ginès et al_1988 29 52 30 53 52.74% 0.97 [0.45, 2.09]
Planas et al_1990 26 43 29 45 42.01% 0.84 [0.36, 2.00]
García-Compeán et al_1993 0 17 0 18 1.99% 1.06 [0.02, 56.24]
Salerno et al_1987 2 20 0 21 3.26% 5.81 [0.26, 128.90]
FE Model for All Studies (Q = 1.38, df = 3, p = 0.71; I2 = 0.0%, τ2 = 0.00) 100.00% 0.97 [0.55, 1.70]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 11 Forest plot for peripheral edema comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for peripheral edema comparing albumin and control; B: Forest plot for peripheral edema comparing albumin *vs* control across other treatment groups. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.

A


Adverse events
Author(s) and Year
Albumin
Control
Weights
Odds Ratio [95% CI]
Events
Total
Events
Total
Caraceni et al_2018 49 218 46 213 74.20% 1.05 [0.67, 1.66]
Solà et al_2018 83 87 84 86 5.18% 0.49 [0.09, 2.77]
Bari et al_2012 3 13 4 12 4.96% 0.60 [0.10, 3.49]
Boyer et al_2016 90 97 88 99 15.65% 1.61 [0.60, 4.33]
FE Model for All Studies (Q = 1.83, df = 3, p = 0.61; I² = 0.0%, τ² = 0.00) 100% 1.05 [0.71, 1.56]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 12 Forest plot for overall AE comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for overall AE comparing albumin and control; B: Forest plot for overall AE comparing albumin *vs* control across other treatment groups.

A


Author(s) and Year
Albumin Events Total
Control Events Total
Weights Odds Ratio [95% CI]
Thévenot etal_2014 27 95 20 96 36.68% 1.51 [0.78, 2.93]
Devisetty et al_2023 6 58 11 116 14.72% 1.10 [0.39, 3.14]
Ginès et al_1988 2 52 2 53 4.05% 1.02 [0.14, 7.52]
Sola-Vera et al_2003 1 37 1 35 2.05% 0.94 [0.06, 15.71]
Jalan et al_2007 1 12 5 12 2.94% 0.13 [0.01, 1.33]
Salerno et al_1987 2 20 3 21 4.46% 0.67 [0.10, 4.48]
García-Compeán et al_1993 0 17 0 18 1.03% 1.06 [0.02, 56.24]
Sort et al_1999 6 63 18 63 16.08% 0.26 [0.10, 0.72]
Appenrodt et al_2008 0 13 0 11 1.01% 0.85 [0.02, 46.42]
Compean et al_2002 0 48 0 48 1.04% 1.00 [0.02, 51.42]
Planas et al_1990 2 43 2 45 4.02% 1.05 [0.14, 7.80]
Fassio et al_1992 0 21 1 20 1.52% 0.30 [0.01, 7.87]
Salerno et al_1991 4 27 3 27 6.30% 1.39 [0.28, 6.91]
Abdel-Khalek and Arif_2010 2 68 2 67 4.09% 0.98 [0.13, 7.20]
FE Model for All Studies (Q = 11.76, df = 13, p = 0.55; I^2 = 0.0%, τ^2 = 0.00) 100% 0.88 [0.59, 1.32]
Favours Albumin
Favours Control
0.05
0.25
1
4
Odds Ratio (log scale)

B



Supplementary Figure 13 Forest plot for in hospital mortality comparing albumin and control and albumin *vs* control across other treatment groups. A: Forest plot for in hospital mortality comparing albumin and control; B: Forest plot for in hospital mortality comparing albumin *vs* control across other treatment groups. 95%CI: 95% confidence interval; df: Degrees of freedom; FE: Fixed effect.


A
Standard Error
0
0.506
1.012
1.518
2.024
-4
-2
0
2
4
Log Odds Ratio
B
Standard Error
0
0.273
0.546
0.818
1.091
-3
-2
-1
0
1
Log Odds Ratio
C
Standard Error
0
0.393
0.787
1.18
1.573
-4
-2
0
2
Log Odds Ratio
D
Standard Error
0
0.413
0.827
1.24
1.654
-4
-2
0
2
Log Odds Ratio
E
Standard Error
0
0.417
0.834
1.251
1.668
-4
-2
0
2
Log Odds Ratio
F
Standard Error
0
0.512
1.024
1.535
2.047
-4
-2
0
2
4
Log Odds Ratio
G
Standard Error
0
0.068
0.136
0.205
0.273
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
Standardized Mean Difference
H
Standard Error
0
0.317
0.634
0.951
1.268
-3
-2
-1
0
1
2
Log Odds Ratio
I
Standard Error
0
0.51
1.019
1.529
2.038
-6
-4
-2
0
2
4
Log Odds Ratio



Supplementary Figure 14 Funnel plot showing symmetric distribution of studies. A: Hyponatremia; B: Paracentesis-induced circulatory dysfunction; C: Severe infection; D: Gastrointestinal bleeding; E: Hepatic encephalopathy; F: Renal impairment; G: Hospital stay days; H: Ascites reappearance; I: Hepatorenal syndrome; J: Spontaneous bacterial peritonitis; K: Mortality during follow up; L: Peripheral edema; M: Overall adverse events; N: In hospital mortality.